Dopamine-Mediated Oxidation of Methionine 127 in α-Synuclein Causes Cytotoxicity and Oligomerization of α-Synuclein

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Nakaso, Kazuhiro ^a   Tajima, Naoko ^a   Ito, Satoru ^a   Teraoka, Mari ^a   Yamashita, Atsushi ^a   Horikoshi, Yosuke ^a   Kikuchi, Daisuke ^a   Mochida, Shinsuke ^a   Nakashima, Kenji ^a   Matsura, Tatsuya ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID; DOPAMINE; METHIONINE; METHIONINE 127; OLIGOMER; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANISOTROPY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATECHOLAMINERGIC SYSTEM; CELL CULTURE; CELL VIABILITY; COMPETITIVE INHIBITION; CYTOTOXICITY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; HUMAN; IN VITRO STUDY; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN TARGETING; WILD TYPE;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; DOPAMINE; GENE EXPRESSION; HUMANS; HYDROGEN PEROXIDE; METHIONINE; OXIDATION-REDUCTION; PARKINSON DISEASE; PC12 CELLS; POINT MUTATION; RATS; RECOMBINANT PROTEINS;

EID: 84874015764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055068     Document Type: Article

References (47)

1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) a-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95: 6469-6473.
2. Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, et al. (2008) Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 363: 2215-2227.
3. Lees AJ, Hardy J, Revesz T, (2009) Parkinson's disease. Lancet 373: 2055-2066.
4. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, et al. (2011) Parkinson disease: the enteric nervous system spills its guts. Neurology 77: 1761-1767.
5. Wakabayashi K, Takahashi H, (1997) Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38Suppl 2: 2-7.
6. Micieli G, Tosi P, Marcheselli S, Cavallini A, (2003) Autonomic dysfunction in Parkinson's disease. Neurol Sci 24: S32-S34.
7. Martin I, Dawson VL, Dawson TM, (2011) Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 12: 301-325.
8. Crosiers D, Theuns J, Cras P, Van Broeckhoven C, (2011) Parkinson's disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42: 131-141.
9. Saiki S, Sato S, Hattori N, (2012) Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry 83: 430-436.
10. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) a-synuclein in Lewy bodies. Nature 388: 839-840.
12. Dickson DW, Liu W, Hardy J, Farrer M, Metha N, et al. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155: 1241-1251.
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
14. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C, (2010) Genetic etiology of Parkinson's disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31: 763-780.
15. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) a-synuclein locus triplication causes Parkinson's disease. Science 302: 841.
16. Chatier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
17. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison E, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171.
18. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC, (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
19. Xu J, Kao SY, Lee FJ, Song W, Jin LW, et al. (2002) Dopamine-dependent neurotoxicity of a-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat Med 8: 600-606.
20. Ito S, Nakaso K, Imamura K, Takeshima T, Nakashima K, (2010) Endogenous catecholamine enhances the dysfunction of unfolded protein response and a-synuclein oligomerization in PC12 cells overexpressing human a-synuclein. Neurosci Res 66: 124-130.
21. Teraoka M, Nakaso K, Kusumoto C, Katano S, Tajima N, et al. (2012) Cytoprotective effect of chlorogenic acid against a-synuclein-related toxicity in catecholaminergic PC12 cells. J Clin Biochem Ntur 51: 122-127.
22. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90: 11282-11286.
23. Iwai A, Yoshimoto M, Masliah E, Saitoh T, (1995) Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34: 10139-10145.
24. Maroteaux L, Campanelli JT, Scheller RH, (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neuosci 8: 2804-2815.
25. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al. (2002) a-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164.
26. Chen L, Periquet M, Wang X, Negro A, McLean PJ, et al. (2009) Tyrosine and serine phosphorylation of a-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257-3265.
27. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
28. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et al. (2001) Ubiquitination of a new form of a-Synuclein by Parkin from human brain: implication for Parkinson's disease. Science 293: 263-269.
29. Leong SL, Pham CL, Galatis D, Fodero-Tavoletti MT, Perez K, et al. (2009) Formation of dopamine-mediated a-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med 46: 1328-1337.
30. Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H, (2007) Cellular oligomerization of a-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem 282: 31612-31630.
31. Zhou W, Long C, Reaney SH, Di Monte DA, Fink AL, et al. (2010) Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta 1802: 322-330.
32. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr, (2001) Kinetic stabilization of the a-synuclein protofibril by dopamine-a-synuclein adduct. Science 294: 1346-1349.
33. Al-Wandi A, Ninkina N, Millership S, Williamson SJ, Jones PA, et al. (2010) Absence of a-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 31: 796-804.
34. Chadchankar H, Ihalainen J, Tanila H, Yavich L, (2011) Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res 1382: 37-44.
35. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ, (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11: 1214-1221.
36. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE, (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54: 691-697.
37. Whitehead RE, Ferrer JV, Javitch JA, Justice JB, (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76: 1242-1251.
38. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R, (2010) a-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 33: 559-568.
39. Bisaglia M, Mammi S, Bubacco L, (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with a-synuclein. J Biol Chem 282: 15597-15605.
40. Yoshimoto Y, Nakaso K, Nakashima K, (2005) L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett 579: 1197-1202.
41. Beyer K, (2006) a-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112: 237-251.
42. Glaser CB, Yamin G, Uversky VN, Fink AL, (2005) Methionine oxidation, a-synuclein and Parkinson's disease. Biochim Biophys Acta 1703: 157-169.
43. Vogt W, (1995) Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med 18: 93-105.
44. Oien DB, Shinogle HE, Moore DS, Moskovitz J, (2009) Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. J Mol Neurosci 39: 323-332.
45. Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, et al. (2007) Methionine sulphoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci 27: 12808-12816.
46. Liu F, Hindupur J, Nguyen JL, Ruf KJ, Zhu J, et al. (2008) Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic Biol Med 45: 242-255.
47. Asanuma M, Miyazaki I, Ogawa N, (2003) Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5: 165-176.